Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Buy
51
HTEC Quote, Financials, Valuation and Earnings
Last price:
$29.37
Seasonality move
:
-4.35%
Day range:
$29.21 - $29.41
52-week range:
$25.69 - $30.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.1K
Avg. volume:
13.2K
1-year change:
4.19%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.41 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.10 | -- | -- | -- | $0.15 | 0.83% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$9.98 | -- | -- | -- | $0.00 | 0% | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$28.99 | -- | -- | -- | $0.47 | 0.49% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.43 | -- | -- | -- | $0.06 | 1.15% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$22.58 | -- | -- | -- | $0.11 | 0.99% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.470 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 1.018 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.174 | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.482 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.079 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 1.371 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
ROBO Global Healthcare Technology & Innovation ETF vs. Competitors
-
Which has Higher Returns HTEC or AGNG?
Global X Aging Population ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Global X Aging Population ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HTEC or AGNG More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, which suggesting that the stock is 7.497% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.780, suggesting its less volatile than the S&P 500 by 21.991%.
-
Which is a Better Dividend Stock HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.15 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or AGNG?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HTEC or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About HTEC or GNOM?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is HTEC or GNOM More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, which suggesting that the stock is 7.497% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.178%.
-
Which is a Better Dividend Stock HTEC or GNOM?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or GNOM?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns HTEC or HRTS?
Tema GLP-1, Obesity & Cardiometabolic ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -
What do Analysts Say About HTEC or HRTS?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema GLP-1, Obesity & Cardiometabolic ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Tema GLP-1, Obesity & Cardiometabolic ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Tema GLP-1, Obesity & Cardiometabolic ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 -
Is HTEC or HRTS More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, which suggesting that the stock is 7.497% more volatile than S&P 500. In comparison Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HTEC or HRTS?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tema GLP-1, Obesity & Cardiometabolic ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.47 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Tema GLP-1, Obesity & Cardiometabolic ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or HRTS?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Tema GLP-1, Obesity & Cardiometabolic ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Tema GLP-1, Obesity & Cardiometabolic ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Tema GLP-1, Obesity & Cardiometabolic ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- --
-
Which has Higher Returns HTEC or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is HTEC or IBBQ More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, which suggesting that the stock is 7.497% more volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.06 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or IBBQ?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns HTEC or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is HTEC or IDNA More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, which suggesting that the stock is 7.497% more volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 0.990, suggesting its less volatile than the S&P 500 by 1.015%.
-
Which is a Better Dividend Stock HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares Genomics Immunology and Healthcare ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.11 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or IDNA?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
